Edition:
India

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

12.22EUR
21 Nov 2017
Change (% chg)

€1.67 (+15.83%)
Prev Close
€10.55
Open
€10.64
Day's High
€12.22
Day's Low
€10.60
Volume
597,883
Avg. Vol
282,461
52-wk High
€15.24
52-wk Low
€8.38

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.27
Market Cap(Mil.): €287.57
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment

07 Sep 2017

BRIEF-Medigene H1 total revenue at EUR 4.9 mln​

* H1 ‍REVENUE FROM CORE BUSINESS IMMUNOTHERAPIES (BLUEBIRD BIO PARTNERSHIP) AMOUNTS TO EUR2,252 K (6M 2016: EUR0 K)​

03 Aug 2017

BRIEF-Medigene submits CTA for its first TCR clinical trial

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT

10 Jul 2017

BRIEF-Medigene says shareholders approve all resolutions

* Says shareholders approve all resolutions with a high majority

24 May 2017

Earnings vs. Estimates